Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Nemolizumab in Atopic Dermatitis
3
Mins
March 2025
Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…
Read more
15
Mins
23 Mar 2021
The Treatment Landscape of Atopic Dermatitis: Interviews with Three Consultant Dermatologists
Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…
12
Mins
23 Mar 2021
Transient Cutaneous Alterations of the Newborn
At birth, the skin of the newborn suddenly comes into contact with the extrauterine world: a dry and aerobic environment.1 Newborn skin is 40–60%…
14
Mins
15 Mar 2021
Syphilis Diagnosis and Treatment: State of The Art
Syphilis is a chronic bacterial infection caused by Treponema pallidum subspecies pallidum, known by clinicians for hundreds of years and with more than 5 million new cases diagnosed every year worldwide…
11
Mins
25 Feb 2021
Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab
The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…
9
Mins
18 Feb 2021
Biological and Clinical Impacts of Ultraviolet-A on the Skin: New Insights
Terrestrial solar UVR consists of UVA (320–400 nm) and UVB (280–320 nm; typically around 295–320nm because of attenuation by the ozone…
11
Mins
10 Feb 2021
Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis
Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…
8
Mins
15 Dec 2020
The Other Side of the Moon: A Clinical Dialogue on the IL-23 Pathway
Prof Reich began by highlighting how insights into the pathophysiology of psoriasis have led to the development and expansion of cytokine-targeted…
6
Mins
15 Dec 2020
Latest Highlights on Biologic Treatments for Psoriasis and Psoriatic Arthritis from EADV 2020
The VOYAGE 1 trial1 was a placebo- and active-controlled Phase III study to evaluate long-term efficacy and safety of the IL-23p19 inhibitor guselkumab…
Loading posts...
« Previous
1
…
8
9
10
11
12
…
27
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View